Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Semaglutide is approved for type 2 diabetes and chronic weight management, significantly lowering HbA1c and body weight by modulating incretin pathways232480, Setmelanotide is approved for chronic weight management in patients with POMC, PCSK1, LEPR deficiencies and Bardet–Biedl syndrome by reducing hunger and promoting weight loss92.
While Semaglutide works as a modified GLP-1(7–37) analog with three key changes—Ala8→Aib, Lys26 acylated with a C18 fatty diacid, and Lys34→Arg—resulting in a long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite23647480, Setmelanotide is a potent synthetic melanocortin-4 receptor (MC4R) agonist derived from a POMC/α-MSH–related sequence that restores downstream MC4R signaling in genetic obesity syndromes3192100.
Semaglutide
GCG
Setmelanotide
POMC
Both peptides fall into a similar broad context as Metabolic peptides, although the details of how they are used and discussed still diverge. Both are often discussed in Metabolic and endocrine contexts, while Semaglutide is more of a hormone peptide and Setmelanotide is better described as a neuropeptide. Both appear to work through Receptor agonist, which is one of the main reasons they can look related despite other differences. Semaglutide has a more synthetic analog origin, while Setmelanotide is closer to synthetic design background. Semaglutide takes the form of a peptide conjugate, whereas Setmelanotide is closer to a cyclic peptide, Semaglutide carries lipidation features, while Setmelanotide instead reflects d-amino acid substitution changes; while their sequence patterns also diverge, with Semaglutide showing alpha-helical domain features and Setmelanotide showing protein-mimetic sequence features.